BTIG analyst Marie Thibault lowered the firm's price target on Outset Medical to $15 from $17 and keeps a Buy rating on the shares. With stability in the company's salesforce, a new product on the way, a broad and growing deal pipeline, strong recurring revenue, and improving margins, this was a solid quarter for rebuilding credibility, the analyst tells investors in a research note.
